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ABSTRACT 
Objectives: Several clinical studies suggest the adipocytokine adiponectin is involved in the 
progression of rheumatoid arthritis (RA). From this point of view, adiponectin might present a 
new therapeutic target. However, as adiponectin also exerts beneficial effects in the human 
organism, a strategy that would allow its detrimental effects to be abolished while maintaining 
the positive effects would be highly favorable. To elucidate such a strategy, we analyzed 
whether the different adiponectin isoforms induce diverging effects, especially with regard to 
RA synovial fibroblasts (SF), a central cell type in RA pathogenesis capable of invading into 
and destroying cartilage. 
Methods: Affymetrix microarrays were used to screen for changes in gene expression of 
RASF. mRNA levels were quantified by real-time PCR, protein levels by immunoassay. 
Migration of RASF and primary human lymphocytes was analyzed using a two-chamber 
migration assay. 
Results: In RASF, the individual adiponectin isoforms induced numerous genes/proteins 
relevant in RA pathogenesis to clearly different extents. In general, the most potent isoforms 
were the high-molecular weight/middle-molecular weight isoforms and the globular isoform, 
while the least potent isoform was the adiponectin trimer. The chemokines secreted by RASF 
upon adiponectin stimulation resulted in an increased migration of RASF and lymphocytes. 
Conclusion: Our results clearly suggest a pro-inflammatory and joint-destructive role of all 
adiponectin isoforms in RA pathophysiology, indicating that in chronic inflammatory joint 
diseases the detrimental effects outweigh the beneficial effects of adiponectin. 
 
 
INTRODUCTION 
 
With 1% prevalence worldwide, rheumatoid arthritis (RA) is a common form of arthritis that 
– although the onset of RA is more frequent later in life – can affect people at any age. 
Without adequate treatment, this severe chronic inflammatory joint disease inevitably causes 
loss of articular function and mobility. Even though nowadays effective therapeutics are 
available against the progression of the disease, additional therapeutic options are still needed 
when current therapies fail or cause severe adverse effects. This is where the so-called 
adipocytokines may come into play. 
The major source of adipocytokines is adipose tissue. It has now become evident that adipose 
tissue is not merely an immunologically inactive type of connective tissue but also an 
important immunoendocrine organ producing hormones and cytokines [1-3]. These factors 
have been collectively termed adipocytokines or – in short – adipokines. Adiponectin (Ad), 
leptin, resistin, and visfatin are just a few examples of this growing number of highly 
bioactive substances with metabolic and immunological functions [4, 5]. 
Pathologically, adipokines appear to be involved in numerous chronic inflammatory diseases. 
This not only includes rheumatoid arthritis (RA) but also systemic lupus erythematosus 
(SLE), ankylosing spondylitis (AS), and systemic sclerosis (SSc) [6]. 
Synovial hyperplasia accompanied by substantial inflammation and degradation of joints [7] 
is a key feature of RA, and RA synovial fibroblasts (SF) are a major player in these 
destructive processes [8-10]. This RA-specific cell type therefore presents a promising target 
for therapeutic intervention. For that reason, we investigated the effects of the adipocytokine 
adiponectin on RASF in order to find out how this may affect the pathogenesis of RA. 
Adiponectin, a C1q/tumor necrosis factor (TNF) homolog [11], lent itself to this question as 
its synovial fluid levels are significantly increased in RA patients compared to osteoarthritis 
(OA) patients as well as healthy controls [12, 13] and hyperadiponectinemia is associated 
with an increased number of joint destructions [14] or radiographic progression [15, 16] in 
RA patients. Of note, adiponectin is not only produced by adipose tissue but also by synovial 
fibroblasts, endothelial cells, osteoblasts, and cardiac myocytes [17-19]. In a previous study 
[20], we could already show that native adiponectin affects several RA effector cells. 
Interestingly, adiponectin is not a homogenous entity but consists of several isoforms 
corresponding to different oligomers with a “bouquet of flower” structure. Trimeric 
adiponectin, also called low-molecular weight (LMW) adiponectin, is composed of three full-
length adiponectin monomers forming a collagen triple helix with a C-terminal globular gC1q 
domain (head domain) [21]. Globular adiponectin (gAd) consists of the head domain of 
trimeric adiponectin as a result of proteolytic cleavage [22-24]. The adiponectin hexamer, the 
so-called middle-molecular weight (MMW) adiponectin, is a combination of two trimeric 
adiponectin molecules, while an assembly of 12 to 18 monomers is collectively termed 
high-molecular weight (HMW) adiponectin [21]. Even though some studies investigated 
selected adiponectin isoforms [21, 25-28], there have not yet been any studies analyzing 
potentially differential effects of adiponectin isoforms on effector cells involved in the 
pathophysiology of RA. 
With adiponectin’s important functions in energy metabolism and beneficial effects on the 
cardiovascular system [29, 30], it might be unadvisable to modulate adiponectin levels 
systemically in order to prevent its disease-promoting effects in RA. Instead, inhibiting 
adiponectin locally at sites of joint destruction or targeting specific isoforms could be viable 
options. Hence, in this study we investigated whether adiponectin isoforms differentially 
affect gene expression and protein secretion of RASF, and could thus provide targets for 
specifically inhibiting the detrimental effects of adiponectin while preserving its beneficial 
effects. As rheumatoid synovium is strongly infiltrated by lymphocytes and migrating RASF, 
which can additionally invade the synovium and cartilage [8], we also analyzed whether the 
factors induced by the different adiponectin isoforms in RASF have chemoattractive 
properties on RASF and lymphocytes. 
MATERIALS & METHODS 
Cell culture 
Human primary synovial fibroblasts and primary lymphocytes were cultured as described 
within the supplementary material. 
Isolation of synovial fibroblasts 
Synovial tissue samples were obtained from synovial biopsy specimens from RA and OA 
patients who were undergoing joint surgery. All specimens were obtained with the approval 
of the Ethics Committee of the Justus-Liebig-University of Gießen. All patients gave 
informed consent and fulfilled the criteria of the American College of Rheumatology [31, 32]. 
Following enzymatic digestion [33, 34], primary synovial fibroblasts were isolated and 
cultured in supplemented DMEM as described previously [20]. 
Isolation of lymphocytes from human whole blood 
Lymphocytes were isolated by Ficoll-based density gradient centrifugation as described in 
more detail within the supplementary material. 
Stimulation of RASF and OASF 
RASF and OASF from passages 3–8 were grown to 70–80% confluency and stimulated with 
25 µg/ml of different human adiponectin forms (BioVendor) for 15 hours: native adiponectin 
(= a mixture of different adiponectin isoforms; recombinantly produced in HEK 293 cells), 
HMW-/MMW-enriched adiponectin (recombinantly produced in HEK 293 cells), trimeric 
adiponectin (recombinantly produced in HEK 293 cells; prevented from further 
oligomerization by a single amino acid mutation), and globular adiponectin (recombinantly 
produced in E. coli). SDS-PAGE analysis images of the commercially available adiponectin 
preparations, which were used, are shown in Supplementary Figure S1. The stimulation time 
was chosen based on preliminary experiments that demonstrated optimal response after 15 
hours [18]. Unstimulated RASF and OASF were used as negative controls. Dose-response 
analyses were performed previously [18] and showed that induction of IL-6 and pro-MMP1 
by adiponectin does not reach a plateau until a concentration of approximately 100 µg/ml. We 
additionally showed that potential LPS contaminations of recombinant adiponectin were not 
responsible for the effects observed after stimulation [20]. 
Affymetrix gene chips 
RASF (passage 5; n=1) were stimulated for 15 hours with 25 µg/ml of the different 
adiponectin isoforms as described above. Affymetrix microarray analysis was performed as 
described within the supplementary material. 
Real-time polymerase chain reaction (PCR) 
Reverse transcription of RNA and real-time PCR were performed as described within the 
supplementary material. 
Immunoassays 
The cytokine, chemokine, MMP, and adiponectin levels in cell culture supernatants were 
measured using commercially available enzyme-linked immunosorbent assays (ELISAs) 
(R&D Systems). 
Two-chamber migration assay 
Media from adiponectin-stimulated RASF were analyzed for their chemoattractive potential 
on RASF and lymphocytes using a two-chamber migration system. The procedure is 
described in detail within the supplementary material. 
Statistical analysis 
Biological or experimental replicates were used to calculate arithmetic means and standard 
errors of the mean (SEM). Data are presented as the mean ± SEM. In order to assess the 
significance of differences, a Student’s 2-tailed t-test was performed for pairwise 
comparisons. For multiple comparisons, ANOVA including Tukey’s post-hoc test was 
performed. P values < 0.05 were considered significant. Statistical calculations were 
performed using Microsoft Excel and GraphPad Prism. 
RESULTS 
Differential induction of chemokines in RASF by adiponectin isoforms 
RASF are an RA-specific cell type capable of driving inflammation and joint destruction [9], 
of invading into cartilage [35], and of migrating from joint to joint [8]. Inhibiting their 
destructive activity is a desirable goal in RA therapy. Factors that promote or inhibit this 
activity are hence of substantial interest as potential therapeutic targets. We therefore 
analyzed the effects of the different adiponectin isoforms on RASF gene expression, focusing 
on finding out whether there are differences in the effects of the adiponectin isoforms and to 
which degree each isoform might be involved in RA pathogenesis. 
First, Affymetrix microarray analysis (GeneChip HG U133A) was performed in order to 
compare the gene expression of RASF stimulated with the different adiponectin isoforms or 
RASF left unstimulated. As large amounts of mRNA are required for Affymetrix microarrays 
and patient material was limited, one RASF population (n=1) was analyzed exemplarily in 
this experiment to screen for changes in gene expression. The variability of different RASF 
populations was later accounted for by verifying selected results with higher n numbers. 
Chemokines were the largest group of dysregulated genes and differentially induced by the 
adiponectin isoforms (Table 1). Verification of selected chemokines (GRO-α/-β/-γ, ENA-78, 
GCP-2, MCP-1, MCP-3) by real-time PCR confirmed the differential induction of mRNA 
expression in multiple RASF populations (Table 2 and Figure 1A). Using immunoassays, we 
confirmed that chemokine secretion (GRO-α, ENA-78, GCP-2, IL-8, MCP-1, RANTES) was 
also differentially regulated by the individual adiponectin isoforms (Table 3 and Figure 1B). 
I-TAC (CXCL11) and MIP-3α (CCL20) protein, however, could not be detected in either cell 
culture supernatants or cell lysates (data not shown). Especially within the real-time PCR and 
immunoassay results, we could identify a distinct pattern regarding the effect of the different 
adiponectin isoforms on RASF: overall, HMW/MMW-enriched and globular adiponectin 
were the most potent isoforms, while the adiponectin trimer was the least effective. Native 
adiponectin, which has been not been enriched for any isoform, mostly held a middle ground 
but was rather variable in its potency depending on the regulated gene or protein. These 
observations are illustrated in Figure 1. 
Differential induction of cytokines, matrix metalloproteinases (MMPs) and other 
RA-related genes in RASF by adiponectin isoforms 
Not only chemokines, but also proinflammatory cytokines, matrix metalloproteinases and 
inflammation-related enzymes play a major role in RA pathogenesis. Their regulation is 
therefore crucial. 
Our results showed that cytokines, MMPs and other RA-related molecules were also regulated 
to very different extents depending on the particular adiponectin isoform (Table 1 and 3, 
Figure 1B). For example, secretion of the proinflammatory cytokine IL-6 was most strongly 
induced by HMW/MMW-enriched adiponectin, while the weakest response was seen with 
trimeric adiponectin. Similar differential inductions by the individual adiponectin isoforms 
could be observed for the inflammation-related enzyme cyclooxygenase 2 (COX2) as well as 
the MMPs 1, 3, 10 and 12. 
Biological variability of RASF cell populations in response to adiponectin stimulation 
Different RASF cell populations, i.e. SF obtained from different RA patients, showed highly 
variable responses to stimulation with adiponectin. Adiponectin upregulated gene expression 
or protein secretion in all cell populations that were analyzed but to very different extents, 
which is illustrated in Figure 2A. 
Response of OASF to adiponectin stimulation in comparison to RASF 
SF from RA patients and OA patients responded similarly to stimulation with adiponectin 
isoforms but OASF generally showed a weaker mean response than RASF, demonstrating the 
special phenotype of RASF (Figure 2B). However, due to the high biological variability of the 
cell populations, statistical significance for the differences between RASF and OASF 
responses could not be reached in most cases. Although the differences in the response 
towards the different adiponectin isoforms were not as prominent as for RASF, differences 
could also be detected for OASF. 
Chemoattractive effect of adiponectin-induced factors on RASF and lymphocytes 
As outlined above, adiponectin isoforms induced numerous chemokines. We therefore 
investigated to which extent this leads to a functional chemoattractive effect on RASF and 
lymphocytes, two key cell types in RA. A two-chamber migration assay was performed with 
RASF and primary human lymphocytes. Conditioned media from RASF cultures incubated 
with the different adiponectin isoforms were used as potential chemoattractants against 
medium from unstimulated RASF incubated in parallel. RASF were allowed to migrate for 15 
hours, lymphocytes for 4 hours. Cells that actively passed the membrane of the two-chamber 
migration system were counted. The gradient-free baseline was set to 100%. 
Here, we observed an increased migration for RASF and lymphocytes towards conditioned 
medium from adiponectin-stimulated RASF, indicating that the adiponectin-induced factors 
have a significant chemoattractive effect on RASF (n=3) (Figure 3A) and lymphocytes (n=3) 
(Figure 3B). Additional controls with adiponectin (25 µg/ml) added just prior to the start of 
the migration assay showed that adiponectin itself does not have any chemoattractive 
properties on the cell types analyzed (data not shown). 
In summary, factors induced by adiponectin isoforms had a differential effect on RASF and 
lymphocyte migration, thus reflecting the individual effects of the respective adiponectin 
isoforms on protein secretion by RASF. 
 
DISCUSSION 
The primary objective of this study was to investigate if the different isoforms of the 
adipokine adiponectin have differential effects on RASF, a key cell type in RA pathogenesis. 
Previous data [14-16, 20] suggest that adiponectin may be rather detrimental in RA and 
involved in disease progression. However, since available data indicate that adiponectin is 
beneficial for metabolic and cardiovascular health [29, 30], systemic elimination in order to 
avoid the harmful effects in RA might not be a favorable option. Based on initial data [27, 
28], researchers concluded that mainly HMW adiponectin is responsible for the vascular-
protective effects of adiponectin. On the other hand, available data suggest that adiponectin 
promotes RA progression [14-16] and does this most likely by inducing the secretion of 
proinflammatory molecules (e.g. IL-6, COX-2), chemokines (e.g. IL-8, MCP-1) and matrix-
degrading enzymes (e.g. MMP3) [20]. Adiponectin is thus able to mount and sustain a 
proinflammatory response in various pathophysiologically relevant cell types in RA and OA, 
including chondrocytes [20, 36, 37] and RASF [20], both of which share the common 
characteristics of mesenchymal-derived cells. 
These results led to the hypothesis that inhibition of specific adiponectin isoforms might help 
circumvent the problem of reducing the harmful effects of adiponectin in RA while 
maintaining its beneficial effects. However, our results showed that even though the 
individual adiponectin isoforms have different potencies to modulate gene expression of 
RASF they do not have opposing effects or no effect at all in the setting of RA 
pathophysiology. Nonetheless, our results suggest that certain isoforms of adiponectin are 
more detrimental in RA than others. Therefore, when considering adiponectin as a 
progression or activity marker for RA, it may be best to look at the most potent isoforms. 
With regard to functional aspects of adiponectin isoforms, we could show that adiponectin-
induced factors promote migration of RASF and lymphocytes in vitro, which in vivo may lead 
to increased synovial lymphocyte infiltration and additional influx of RASF to sites of 
inflammation and cartilage degradation. Inhibition of these processes by blocking the local 
effects of specific adiponectin isoforms within the joints could therefore lead to reduced 
disease progression and activity. 
Another interesting observation was the high variability of RASF in response to adiponectin 
isoform stimulation, which may be attributed to different genetic profiles [38, 39] as well as 
epigenetic variations between RASF populations [40]. This is also in line with clinical 
findings showing that there are considerable differences in how RA patients respond to the 
different available medications. RASF possess a special phenotype reflected not only in their 
ability to migrate and invade into cartilage [8] but also in their ability to respond to external 
stimuli such as adiponectin, which was illustrated here by the weaker response of OASF to 
adiponectin compared to RASF. 
When considering strategies for modulating the effects of adiponectin, there are other 
conceivable options besides modulating adiponectin itself: targeting adiponectin receptors 
[41-43] or co-receptors [44-47], and inhibiting the oligomerization of adiponectin isoforms by 
small molecule inhibitors that prevent the assembly into higher molecular weight isoforms. 
With respect to animal models, the viability of adiponectin knock-out (KO) mice indicates 
that, at least in mice, adiponectin is not vital, but results regarding the effects of adiponectin 
knock-out or overexpression in vivo are controversial. While Shinoda et al. [48] found no 
abnormalities regarding bone mass and turnover in Ad-/Ad- mice, Williams et al. [49] as well 
as Oshima et al. [50] found an increased bone density. Conversely, adiponectin 
overexpressing mice had increased bone mass, parameters of bone resorption and bone 
erosion were not affected [51]. Contrary to what we would have expected based on our 
results, adenovirus-mediated systemic expression of human adiponectin in collagen-induced 
arthritis (CIA) mice reduced clinical disease activity scores of CIA [52]. Most likely, this 
result reflects the distinct phenotype of human RASF and the difference between human and 
murine arthritides. 
Several groups also analyzed the overexpression or knockdown of adiponectin in mouse 
models in the metabolic and vascular context [53-57]. Under special nutritional conditions 
(high-fat and/or high-glucose diet) or on an obesity background (ob/ob), anti-diabetic and 
anti-atherogenic properties were observed for overexpression of adiponectin, while 
adiponectin knockout resulted in insulin resistance and impaired glucose metabolism. 
Therefore, it is always important to consider the experimental environment when looking at 
the in vivo effects of adiponectin. 
Also, as yet nothing is known about the role of adiponectin isoforms in mice, their occurrence 
and distribution. It therefore remains questionable to what extent the existing adiponectin KO 
mouse models are able to provide hints on how adiponectin isoform deprivation would affect 
human RA. 
In conclusion, while adiponectin may present an interesting therapeutic target in RA, more 
research is required to elucidate whether adiponectin isoforms can be targeted specifically and 
respective inhibitors can be used to provide new therapeutic approaches. Nonetheless, the 
clearly different potencies of adiponectin isoforms in RA suggest that considering the 
isoforms may be of value when utilizing adiponectin as a marker for risk, activity or 
progression of RA. 
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FIGURE LEGENDS 
Figure 1. 
(A) Differential induction of chemokine mRNA expression in RASF by adiponectin isoforms 
(real-time PCR data). Multiple RASF populations (n=4) were stimulated with adiponectin 
isoforms or left unstimulated (control). x-fold changes in mRNA expression of several 
chemokines were determined by real-time PCR and are shown (as arithmetic mean) in 
comparison for all adiponectin isoforms used for stimulation. 
(B) Differential induction of cytokine, chemokine and matrix metalloproteinase (MMP) 
secretion by RASF upon stimulation with adiponectin isoforms. Multiple RASF populations 
(n=4–15, cf. Table 3) were stimulated with adiponectin isoforms or left unstimulated 
(control). x-fold changes in protein secretion of cytokines, chemokines and MMPs were 
determined by ELISA and are shown (as arithmetic mean) in comparison for all adiponectin 
isoforms used for stimulation. 
 
Figure 2. 
(A) Biological variability of RASF cell populations in response to adiponectin stimulation. 
Chemokine (ENA-78 and IL-8), cytokine (IL-6) and matrix metalloproteinase (MMP3) 
secretion was quantified by ELISA after adiponectin stimulation of cultured RASF from 
different RA patients. To illustrate the biological variability of RASF populations in response 
to adiponectin stimulation, the individual results (x-fold changes in protein secretion) are 
shown as dots. The arithmetic mean is displayed as a bar. 
(B) Response of OASF to adiponectin stimulation in comparison to RASF. Multiple OASF 
populations (n=4 for GRO-α; n=12 for GCP-2; n=4 for RANTES; n=12 for MCP-1 / native 
Ad and n=8 for MCP-1 / other Ad) were stimulated with adiponectin isoforms in parallel to 
multiple RASF populations (cf. Table 3 for n numbers). Chemokine secretion was quantified 
by ELISA. Black bars indicate x-fold changes in protein secretion for RASF, while white bars 
indicate x-fold changes in protein secretion for OASF (each compared to unstimulated 
controls). Data are shown as the mean ± SEM. 
 
Figure 3. 
(A) Chemoattractive effect of adiponectin-induced factors on RASF. Medium from RASF 
stimulated with different adiponectin isoforms was used in a two-chamber migration assay as 
a chemoattractant for RASF (n=3). The baseline (without chemotactic gradient) was set to 
100%. Migration of RASF is expressed relative to the baseline. Using serum-free medium as 
a chemorepellent decreased RASF migration to 38%, while using 10% FCS medium as a 
positive control increased RASF migration by 278% (data not shown). 
(B) Chemoattractive effect of adiponectin-induced factors on lymphocytes. Medium from 
RASF stimulated with different adiponectin isoforms was used in a two-chamber migration 
assay as a chemoattractant for lymphocyte (n=3) and analyzed as described above. Using 
serum-free medium as a chemorepellent decreased lymphocyte migration to 35%, while using 
RANTES (10 ng/ml) + SDF (100 ng/ml) as a positive control increased lymphocyte migration 
by 345% (data not shown). 
Data are shown as the mean ± SEM. * p<0.05; ** p < 0.01; *** p < 0.001 
 
Table I Affymetrix microarray results: Differential gene induction in 
 RASF by adiponectin isoforms 
Gene Name Gene 
Symbol 
Fold 
Change 
Native Ad 
Fold 
Change Ad 
HMW/MMW 
Fold 
Change  
Ad Trimer 
Fold 
Change 
gAd 
Chemokines      
Chemokine (C-C motif) ligand 2 (CCL2) MCP-1 4.8 4.7 3.4 5.8 
Chemokine (C-C motif) ligand 5 (CCL5) RANTES 24.0 24.7 3.8 73.2 
Chemokine (C-C motif) ligand 7 (CCL7) MCP-3 101.3 74.9 28.0 254.0 
Chemokine (C-C motif) ligand 8 (CCL8) MCP-2 25.8 11.2 3.5 297.3 
Chemokine (C-C motif) ligand 20 (CCL20) MIP-3α 1424.0 1547.0 82.9 728.3 
Chemokine (C-X-C motif) ligand 1 (CXCL1) GRO-α 29.4 33.3 17.7 32.8 
Chemokine (C-X-C motif) ligand 2 (CXCL2) GRO-β 33.5 43.9 12.6 19.7 
Chemokine (C-X-C motif) ligand 3 (CXCL3) GRO-γ 99.6 234.0 34.6 60.2 
Chemokine (C-X-C motif) ligand 5 (CXCL5) ENA-78 37.8 121.7 9.1 12.6 
Chemokine (C-X-C motif) ligand 6 (CXCL6) GCP-2 5.5 5.6 3.7 4.1 
Chemokine (C-X-C motif) ligand 8 (CXCL8) IL-8 43.4 50.5 28.2 47.6 
Chemokine (C-X-C motif) ligand 9 (CXCL9) MIG 9.3 36.7 -3.1 48.9 
Chemokine (C-X-C motif) ligand 10 (CXCL10) IP-10 161.0 78.6 2.1 1225.0 
Chemokine (C-X-C motif) ligand 11 (CXCL11) I-TAC 130.9 88.0 -4.4 728.3 
Cytokines      
Interleukin 6 IL-6 6.4 6.5 6.6 8.9 
Interleukin 11 IL-11 24.3 441.0 157.4 2.3 
Other Inflammatory Molecules      
Prostaglandin E synthase PTGES 3.4 4.6 2.4 9.4 
Prostaglandin endoperoxide synthase 2 / 
cyclooxygenase 2 
PTGS2/ 
COX2 19.9 17.9 7.1 26.1 
Pre-B-Cell Growth & B-Cell Activation      
Bone marrow stromal cell antigen 2 BST2 200.8 100.4 28.0 1091.0 
Receptors      
Interleukin 7 receptor IL7R 5.6 6.9 3.0 8.9 
Interleukin 17 receptor B IL17RB 2.6 2.1 1.0 2.8 
Proteinases & Peptidases      
Matrix metallopeptidase 1 (interstitial 
collagenase) MMP1 11.6 13.6 5.2 12.4 
Matrix metallopeptidase 3 (stromelysin 1 
progelatinase) MMP3 62.5 115.6 36.3 16.2 
Matrix metallopeptidase 10 (stromelysin 2) MMP10 88.7 599.9 94.4 17.0 
Matrix metallopeptidase 12 (macrophage 
elastase) MMP12 49.9 222.7 10.1 12.6 
Bone Metabolism      
Stanniocalcin 1 STC1 19.8 23.4 14.5 24.6 
Growth Factors      
Fibroblast growth factor 10 FGF10 5.0 5.6 1.0 3.9 
RASF (n=1) were treated with adiponectin isoforms or left untreated (control). Affymetrix microarray analysis (GeneChip HG 
U133A) was performed as described. The results indicate that genes from several functional groups are differentially regulated in 
RASF by adiponectin isoforms. The cut-off value for fold changes was ≤-2 (repression) or ≥2 (induction), respectively. Strongly 
repressed genes were low in number and of no known or well defined function. 
Table II Differentially induced chemokine mRNA expression in 
 RASF by adiponectin isoforms 
Gene Name Symbol Ad 
Isoform 
Fold 
Change 
SEM n  p 
Chemokine (C-X-C motif) ligand 1 (CXCL1) GRO-α native 23.9 8.9 4  0.036 
  HMW/MMW 
trimer 
globular 
148.0 
14.1 
206.8 
85.4 
8.1 
134.9 
4 
4 
4 
 0.009 
 0.021 
 0.009 
Chemokine (C-X-C motif) ligand 1 (CXCL2) GRO-β native 23.3 8.0 4  0.054 
  HMW/MMW 
trimer 
globular 
106.2 
9.3 
121.1 
57.5 
4.5 
68.8 
4 
4 
4 
 0.008
 0.021 
 0.008 
Chemokine (C-X-C motif) ligand 1 (CXCL3) GRO-γ native 66.3 50.8 4  0.020 
  HMW/MMW 
trimer 
globular 
77.7 
4.9 
33.3 
36.7 
1.9 
13.4 
4 
4 
4 
 0.005 
 0.072 
 0.008 
Chemokine (C-X-C motif) ligand 5 (CXCL5) ENA-78 native 70.8 41.9 4  0.006 
  HMW/MMW 
trimer 
globular 
57.7 
3.8 
22.2 
24.7 
0.6 
8.4 
4 
4 
4 
 0.002 
 0.002 
 0.054 
Chemokine (C-X-C motif) ligand 6 (CXCL6) GCP-2 native 112.0 45.7 4  0.019 
  HMW/MMW 
trimer 
globular 
584.6 
22.3 
410.2 
327.7 
14.8 
233.7 
4 
4 
4 
 0.003 
 0.025 
 0.003 
Chemokine (C-C motif) ligand 2 (CCL2) MCP-1 native 7.2 1.9 4  0.008 
  HMW/MMW 
trimer 
globular 
11.9 
2.7 
57.9 
3.0 
0.5 
20.2 
4 
4 
4 
 0.005 
 0.013 
 0.005 
Chemokine (C-C motif) ligand 7 (CCL7) MCP-3 native 16.3 9.1 4  0.015 
  HMW/MMW 
trimer 
globular 
17.8 
3.9 
56.1 
7.9 
2.4 
38.1 
4 
4 
4 
 0.007 
 0.151 
 0.077 
Multiple populations of RASF (n=4) were stimulated with different adiponectin isoforms. RNA was isolated, reverse 
transcribed to cDNA and quantified by real-time PCR. Fold changes in mRNA expression (as compared to an 
unstimulated control), biological variability indicated by the standard error of mean (SEM), number of populations 
analyzed (n), and the p-values are presented. 
Table III Differentially induced cytokine, chemokine and MMP 
 secretion in RASF by adiponectin isoforms 
Protein Name Symbol Ad 
Isoform 
Fold 
Change 
SEM n  p 
Chemokines       
Chemokine (C-X-C motif) ligand 1 (CXCL1) GRO-α native 125.1 43.0 9  0.024 
  HMW/MMW 
trimer 
globular 
150.9 
19.0 
75.8 
44.8 
12.5 
26.4 
5 
5 
5 
 0.023 
 0.223 
 0.027 
Chemokine (C-X-C motif) ligand 5 (CXCL5) ENA-78 native 22.5 6.2 13  0.005 
  HMW/MMW 
trimer 
globular 
29.5 
9.9 
14.8 
5.4 
3.9 
5.2 
8 
8 
8 
 0.001 
 0.056 
 0.033 
Chemokine (C-X-C motif) ligand 6 (CXCL6) GCP-2 native 58.5 23.1 15  0.026 
  HMW/MMW 
trimer 
globular 
164.1 
22.8 
110.3 
36.4 
6.1 
35.8 
14 
14 
14 
 0.001 
 0.003 
 0.009 
Chemokine (C-X-C motif) ligand 8 (CXCL8) IL-8 native 611.3 193.2 14  0.008 
  HMW/MMW 
trimer 
globular 
953.2 
135.6 
570.5 
275.0 
50.8 
223.1 
14 
14 
14 
 0.004 
 0.020 
 0.024 
Chemokine (C-C motif) ligand 2 (CCL2) MCP-1 native 15.8 3.6 13  0.001 
  HMW/MMW 
trimer 
globular 
23.0 
17.2 
18.5 
4.15 
7.9 
6.9 
8 
8 
8 
 0.001 
 0.081 
 0.040 
Chemokine (C-C motif) ligand 5 (CCL5) RANTES native 44.4 25.1 8  0.127 
  HMW/MMW 
trimer 
globular 
77.5 
10.0 
145.3 
17.8 
7.8 
35.6 
8 
8 
8 
 0.004 
 0.381 
 0.005 
Cytokines       
Activin A INHBA native 15.1 6.0 9  0.047 
  HMW/MMW 
trimer 
globular 
32.0 
7.3 
2.8 
9.8 
2.2 
1.2 
4 
4 
4 
 0.099 
 0.065 
 0.212 
Interleukin 6 IL-6 native 31.2 9.7 12  0.010 
  HMW/MMW 
trimer 
globular 
57.0 
20.7 
26.8 
16.9 
7.1 
9.9 
12 
12 
12 
 0.007 
 0.019 
 0.024 
Proteinases & Peptidases       
Matrix metallopeptidase 1, propeptide pro-MMP1 native 11.9 8.1 13  0.206 
 
 HMW/MMW 
trimer 
globular 
24.4 
8.2 
6.5 
15.9 
5.1 
1.8 
13 
13 
13 
 0.014 
 0.185 
 0.028 
Matrix metallopeptidase 3 MMP3 native 10.3 3.5 10  0.025 
 
 HMW/MMW 
trimer 
globular 
19.2 
4.3 
12.6 
4.1 
1.5 
3.8 
8 
8 
8 
 0.001 
 0.063 
 0.014 
Matrix metallopeptidase 10 MMP10 native 4.4 1.1 11  0.009 
 
 HMW/MMW 
trimer 
globular 
11.6 
2.7 
4.7 
2.1 
0.5 
1.5 
11 
11 
11 
 0.002 
 0.006 
 0.043 
Multiple populations of RASF (n=4-15) were stimulated with different adiponectin isoforms. Secreted chemokines, 
cytokines, and matrix metalloproteinases were quantified by immunoassays. Fold changes of secretion (as compared to 
an unstimulated control), biological variability indicated by the standard error of mean (SEM), number of populations 
analyzed (n), and the p-values are presented. 
 
